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Abstract
Background: Randomized clinical trials showed the benefit of pharmacological and revascularization
treatments in secondary prevention of myocardial infarction (MI), in selected population with highly
controlled interventions. The objective of this study is to measure these treatments' impact on the
cardiovascular (CV) mortality rate among patients receiving usual care in the province of Quebec.
Methods: The study population consisted of a "naturalistic" cohort of all patients ≥ 65 years old living in
the Quebec province, who survived a MI (ICD-9: 410) in 1998. The studied dependant variable was time
to death from a CV disease. Independent variables were revascularization procedure and cardioprotective
drugs. Death from a non CV disease was also studied for comparison. Revascularization procedure was
defined as percutaneous transluminal coronary angioplasty (PTCA) or coronary artery bypass graft
(CABG). The exposure to cardioprotective drugs was defined as the number of cardioprotective drug
classes (Acetylsalicylic Acid (ASA), Beta-Blockers, Angiotensin-Converting Enzyme (ACE) Inhibitors,
Statins) claimed within the index period (first 30 days after the index hospitalization). Age, gender and a
comorbidity index were used as covariates. Kaplan-Meier survival curves, Cox proportional hazard
models, logistic regressions and regression trees were used.
Results: The study population totaled 5596 patients (3206 men; 2390 women). We observed 1128 deaths
(20%) within two years following index hospitalization, of them 603 from CV disease. The CV survival rate
at two years is much greater for patients with revascularization, regardless of pharmacological treatments.
For patients without revascularization, the CV survival rate increases with the number of cardioprotective
drug classes claimed. Finally, Cox proportional hazard models, regression tree and logistic regression
analyses all revealed that the absence of revascularization and, to a lower extent, absence of
cardioprotective drugs were major predictors for CV death, even after adjusting for age, gender and
comorbidity.
Conclusion: Considering usual care management of MI in the province of Quebec in 1998, CV survival
is positively correlated to the presence of a revascularization procedure and to the intensity of
cardioprotective pharmacological treatment. These results are coherent with data from randomized
control trials.
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Background
Cardiovascular events represent a major health burden for
Canada and other modern societies and myocardial inf-
arction (MI) accounts for a large percentage of them. MI is
a very lethal disease with near 30% of deaths, among
which near half occurs before arriving to hospital [1]. The
prognosis of this clinical event depends on the patient's
acknowledgement of his clinical symptoms and the deci-
sion to seek for medical care; on the delay between the
first symptoms and the arrival to hospital (onset-to-door);
on the emergency care team rapidity of response, and on
the swiftness and suitability of the treatment received dur-
ing hospitalization [2,3], but also after discharge. MI sec-
ondary prevention includes all clinical measures taken
after the event's occurrence to reduce mortality and/or
morbidity of the disease. Cardiovascular secondary pre-
vention includes appropriate revascularization proce-
dures and long term use of known cardioprotective drugs
– Acetylsalicylic Acid (ASA), Beta-Blockers, Angiotensin-
Converting Enzyme (ACE) Inhibitors, Statins – as well as
risk factors reduction with long term lifestyle and/or drug
management. Practice guidelines regarding MI manage-
ment have been widely published in the last decade [4-7].
These clinical guidelines are based on evidence that early
revascularization reduces mortality and morbidity [8-12].
However, some clinical trials showed only marginal ben-
efits of revascularization [13,14]. Each of the four phar-
macological classes included in the guidelines has also
individually demonstrated great benefits to prevent mor-
tality and morbidity in secondary prevention [15-36].
Some combinations of these drug classes have also
showed reduced mortality [37-39]. In 2004, Mukherjee et
al [40] have demonstrated an improvement in 6-month
mortality after an acute coronary syndrome according to a
composite appropriateness score defined by a combina-
tion of these four drug classes. To our knowledge, little is
known about the impact of the combination of these four
classes of drugs in addition to revascularization procedure
in the general population.
The main objective of this study is to measure in the con-
text of usual care, the impact of surgical (PTCA and
CABG) and pharmacological treatments (revasculariza-
tion and/or the number of type of cardioprotective drugs
claimed) on the cardiovascular (CV) survival rate of
patients with MI in 1998 in Quebec.
Methods
Design
We conducted a population-based cohort study using sec-
ondary data analysis from the Quebec's hospital discharge
register (MED-ECHO). This register provides administra-
tive data on patients hospitalized in the province of Que-
bec. Studies confirming the validity of the administrative
hospital discharge data concerning MI have previously
been published [41,42].
Studied population
The study population included all patients 65 years and
older living in the province of Quebec, who have been
hospitalized in Quebec for a MI between January 1st and
December 31st 1998. We will refer as the "index period"
the period defined by the first hospitalization in addition
to a 30-day period after discharge from the index hospital-
ization. We included patients who were hospitalized for
acute myocardial infarction (code 410 of the Interna-
tional Disease Classification, 9th revision (IDC-9)) as the
main diagnosis. Patients with a MI in the year preceding
the index hospitalization were excluded in order to
include only new or stable MI cases. Patients from north-
ern and low populated regions (Northern Quebec, Nunavik
and James Bay Cree Lands) were excluded as well because
of major cultural, social and health care services differ-
ences. In order to measure the pharmacological treat-
ments claimed after the MI event, only patients who
survived the index period were included in the analyses. A
2-year follow-up period was retained to collect the date
and cause of death.
Data sources
All patients' data were obtained from the Quebec's hospi-
tal discharge register (MED-ECHO) and the provincial
demographic database. For claimed drugs, we used the
provincial pharmacological register administered by the
Régie de l'assurance maladie du Québec (RAMQ), which cov-
ers almost all people aged 65 years or more as well as wel-
fare recipients and people not covered by private drug
insurance.
Studied variables
The main outcome of interest was time to death from CV
cause (ICD-9: 410–414, 426–429). Exposure to revascu-
larization was defined as 1 if there was mention of a PTCA
or a CABG, as coded in the Quebec's hospital discharge
register (Canadian Classification of diagnostic, therapeu-
tic and surgical procedures (CCP) beginning with 480 to
483), for the index period and 0 otherwise. Exposure to
medication was defined as the number of cardioprotective
drug classes that was claimed within the index period. The
following drug classes were considered: ASA, β-blockers,
ACE inhibitors, and Statins.
Covariates included gender, age, and a comorbidity index.
This index is an adaptation of the D'Hoore index, which is
itself an adaptation of the Charlson comorbidity index [43].
The D'Hoore index is a weighted score of comorbid con-
ditions, these conditions being defined by the secondary
diagnoses available in the MED-ECHO database in the
year preceding the index hospitalization. We adapted thisBMC Cardiovascular Disorders 2006, 6:21 http://www.biomedcentral.com/1471-2261/6/21
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index simply by substracting the quantity 1 to the
D'Hoore index, corresponding to the weight associated to
the MI comorbid condition.
Statistical analyses
The chi-square test was used for comparison between pro-
portions, whereas for comparison between means, the t-
test or ANOVA was used depending on the number of
groups. Survival analyses were done using Kaplan-Meier
estimates for unadjusted survival curves (the homogene-
ity between the curves is tested using the Wilcoxon statis-
tics) and Cox proportional hazard model to obtain death
rates adjusted for all the covariates. Logistic regression
[44] and regression tree [45,46] analyses were also per-
formed to predict the CV death rate after two years. In
regression tree methodology, information on a data set is
summarized by dividing the population into a number of
subgroups, as homogeneous as possible but distinct with
respect to the parameters to predict. The subgroups are
identified by a tree-structured figure of binary questions
on the predictors. The resulting classification is the most
informative one with respect to the parameter in question.
Tree-growing techniques [47-49] are particularly suited to
handle a large number of variables including some with
missing values and to investigate the interactions between
them. For all approaches, the potential patient-level pre-
dictors were age, gender, the comorbidity index, the pres-
ence/absence of a revascularization and the number of
cardioprotective drugs claimed within the index period.
The trees were pruned at a significance level of 0.001. For
all other tests, the significance level used was 0.05. Statis-
tical analyses were done using SAS Release 9.1 and the
RTREE program [45,46].
Ethical considerations
This project was approved by the Sherbrooke University
Hospital Ethics Board and the Commission d'accès à l'infor-
mation du Québec.
Results
A total of 7332 patients 65 years or older have been hos-
pitalized for a MI in Quebec between January 1st, 1998
and December 31st, 1998. Of those, 172 patients were
excluded because they had a MI in the prior year, and 11
because they lived in the Quebec Northern regions. From
the remaining 7149 patients, 1553 (21,7%) died at the
index period and were removed from the analyses. There-
fore, the study population includes 5596 patients, men
accounting for 57% (n = 3206) of it. Table 1 presents the
cohort's characteristics in regard to gender, age and
comorbidity index, according to whether they survived
the index period or not. Men, younger patients and
patients with a lower comorbidity index are more repre-
sented in the cohort who survived the index period. Table
2 presents the patients' characteristics according to the
revascularization procedure and to the number of cardio-
protective drug classes claimed during the index period.
This table reveals that men and younger patients, as well
as patients with a lower comorbidity index have more
chances of receiving a revascularization. On the other
hand, age and comorbidity index, but not gender, are sta-
tistically associated with the number of cardioprotective
drug classes claimed at the index period.
Of the 5596 cohort patients who survived the index
period, 603 (10.8%) died from CV disease and 525
(9.4%) from another cause. Table 3 presents a cross tabu-
Table 1: Description of the population with MI in Quebec in 1998
Total population Died at index period Survived index period p-value
TOTAL 7149 1553 (21.7%) 5596 (78.3%)
Gender
Men 3982 (55.7%) 776 (50.0%) 3206 (57.3%) < .0001
Women 3167 (44.3%) 777 (50.0%) 2390 (42.7%)
Age
Mean ± SD 76.1 ± 7.3 78.9 ± 7.5 75.3 ± 7.0 < .0001
65–74 years 3298 (46.1%) 487 (31.4%) 2811 (50.2%) < .0001
75–84 years 2823 (39.5%) 674 (43.4%) 2149 (38.4%)
≥ 85 years 1028 (14.4%) 392 (25.2%) 636 (11.4%)
Comorbidity index
Mean ± SD (median) 1.8 ± 1.9 (1) 2.4 ± 2.1 (2) 1.6 ± 1.8 (1) < .0001
0 2345 (32.8%) 333 (21.4%) 2012 (36.0%) < .0001
1–2 2624 (36.7%) 547 (35.2%) 2077 (37.1%)
3–4 1538 (21.5%) 427 (27.5%) 1111 (19.9%)
5–6 499 (7.0%) 181 (11.7%) 318 (5.7%)
≥ 7 143 (2.0%) 65 (4.2%) 78 (1.4%)BMC Cardiovascular Disorders 2006, 6:21 http://www.biomedcentral.com/1471-2261/6/21
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lation of the covariates including care (revascularization
and cardioprotective drugs) and the 2-year death rates.
Here again, younger patients and patients with low
comorbidity index have lower CV death rates and non CV
death rates at 2 years. More than 1 out of 8 patients
(12.7%) on which no revascularization was performed at
the index period died from a CV cause after 2 years, and
10.7% from another cause. However the differences in
death rates between PTCA and CABG were not statistically
significant. Similarly, one out of six (15.5%) patients who
did not claim any cardioprotective drugs within the first
30 days after the index hospitalization died from CV dis-
ease within 2 years. Here again, patients receiving the
most intensive treatment (all four cardioprotective drug
classes combined) benefited the most. The same trend is
also observed in non CV death rates but to a lesser extent.
The cardiovascular survival is clearly demonstrated in Fig-
ure 1 to Figure 3 where unadjusted Kaplan-Meier esti-
mates show basically the same relation between the
revascularization, the number of cardioprotective drug
classes claimed at the index period and the CV survival
rate. These curves also demonstrate that CV survival rate is
greater for patients with revascularization, regardless of
the number of cardioprotective drug classes claimed at the
Unadjusted Kaplan-Meier cardiovascular (CV) survival curves  according to the number of cardiovascular drug classes  claimed during index period among survivors at 30 days who  did not receive a revascularization (n = 4473) Figure 2
Unadjusted Kaplan-Meier cardiovascular (CV) sur-
vival curves according to the number of cardiovascu-
lar drug classes claimed during index period among 
survivors at 30 days who did not receive a revascular-
ization (n = 4473). * The curves are statistically different (p 
< .0001)
Table 2: Characteristics of MI patients according to exposure to revascularization and medication (n = 5596)
Total Men Women Age (years) Mean (± SD) Comorbidity index Mean (± SD)
Revascularization
No 4473 2505 (56.0%)a 1968 (44.0%) 76.2 (± 7.2)b 1.7 (± 1.8)b
Yes 1123 701 (62.4%) 422 (37.6%) 72.0 (± 5.2) 1.3 (± 1.5)
PTCA 767 470 (61.3%) 297 (38.7%) 72.1 (± 5.4) 1.1 (± 1.4)
CABG 356 231 (64.9%) 125 (35.1%) 71.6 (± 4.7) 1.5 (± 1.6)
Number of drug classes
0 757 413 (54.6%)c 344 (45.4%) 76.3 (± 8.0)b 2.0 (± 1.9)b
1 1166 682 (58.5%) 484 (41.5%) 76.5 (± 7.1) 1.8 (± 1.8)
2 2046 1190 (58.2%) 856 (41.8%) 75.4 (± 6.9) 1.6 (± 1.8)
3 1315 741 (56.3%) 574 (43.7%) 74.0 (± 6.4) 1.4 (± 1.6)
4 312 180 (57.7%) 132 (42.3%) 73.4 (± 5.6) 1.5 (± 1.6)
a The difference between rates of men according to revascularization is statistically significant (p = 0.0003)
b The differences between means (age and Comorbidity index) according to revascularization and number of drug classes are all statistically 
significant (p < .0001)
c The difference between rates of men according to number of drug classes is not statistically significant (p = 0.3889)
Unadjusted Kaplan-Meier cardiovascular (CV) survival curves  according to presence/absence of revascularization during  index period among survivors at 30 days (n = 5596)* Figure 1
Unadjusted Kaplan-Meier cardiovascular (CV) sur-
vival curves according to presence/absence of revas-
cularization during index period among survivors at 
30 days (n = 5596)*. * The curves are statistically different 
(p < .0001).BMC Cardiovascular Disorders 2006, 6:21 http://www.biomedcentral.com/1471-2261/6/21
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index period. For patients without revascularization, CV
survival rate increases with the number of cardioprotec-
tive drugs claimed (Figure 2).
Cox proportional hazard models (Table 4) show that
adjusted CV death rate increases with age and also with
comorbidity index. The hazard ratio (HR) is much lower
for patients with revascularization as well as proportion-
ally with the number of classes of cardioprotective drugs
claimed.
Regression tree and logistic regression analyses (Figure 4)
provide complementary information on variables related
to a greater chance of survival 2 years after a MI. The CV
death rates vary from 0.1% for younger individuals who
had a revascularization with no comorbid conditions to
39.1% for very old patients with comorbidities. For older
patients without comorbidities, the use of cardioprotec-
tive drugs lowers the 2-year death rates from 22.2% to
8.6%. For younger patients with comorbidities, revascu-
larization decreases the death rates from 9.4% to 3.6%.
Discussion
The major findings of this population-based cohort study
are that CV survival is strongly correlated with revascular-
ization and, at a lesser extent, to the number of classes of
cardioprotective drugs claimed. Moreover, the benefit
seems to be additive. It is not surprising that populations
with and without revascularization differ in age, sex and
comorbidity index. However, even after controlling for
these factors (Cox proportional hazard model), CV sur-
vival remains strongly correlated with revascularization.
Differences between the survival curves may possibly
reflect clinical differences unconsidered in the comorbid-
ity index, like non-Q wave myocardial infarction [50,51].
It may also reflect the socio-economical status related to
the patient or broader variables like the care setting
[52,53], or geographical factors like rural – urban differ-
ences [54-56]. This study also demonstrates that survival
rate increases with the number of cardioprotective drugs
claimed. Similar results were found by Murkherjee et al
[40] using an appropriateness algorithm for the use of
each secondary pharmacological prevention strategies. In
their paper, the score was dependent on the number of
Unadjusted Kaplan-Meier cardiovascular (CV) survival curves  according to the number of cardiovascular drug classes  claimed during index period among survivors at 30 days who  received a revascularization (n = 1123) Figure 3
Unadjusted Kaplan-Meier cardiovascular (CV) sur-
vival curves according to the number of cardiovascu-
lar drug classes claimed during index period among 
survivors at 30 days who received a revascularization 
(n = 1123). * The curves are statistically different (p = 
0.006)
Table 3: Two-year death rates according to patients' 
characteristics and exposure to revascularization and 
medication (n = 5596)
Total 2-year CV death 2-year non-CV death
Total 5596 603 (10.8%) 525 (9.4%)
Mean Age ± SD 5596 79.3 ± 7.3 77.0 ± 7.4
Gender
Women 2390 291 (12.2%)a 215 (9.0%)d
Men 3206 312 (9.7%) 310 (9.7%)
Comorbidity index
Mean ± SD (median) 5596 2.6 ± 1.9 (2) 2.6 ± 2.1 (2)
02 0 1 2 8 3  ( 4 . 1 % ) b 89 (4.4%)b
1–2 2077 227 (10.9%) 188 (9.0%)
3–4 1111 197 (17.7%) 152 (13.7%)
5–6 318 77 (24.2%) 72 (22.6%)
≥ 7 78 19 (24.4%) 24 (30.8%)
Revascularization
No 4473 567 (12.7%)c 478 (10.7%)c
Yes 1123 36 (3.2%) 47 (4.2%)
PTCA 767 24 (3.1%)d 33 (4.3%)d
CABG 356 12 (3.4%) 14 (3.9%)
Number of drug classes
0 757 117 (15.5%)e 113 (14.9%)e
1 1166 162 (13.9%) 136 (11.7%)
2 2046 207 (10.1%) 178 (8.7%)
3 1315 103 (7.8%) 78 (5.9%)
4 312 14 (4.5%) 20 (6.4%)
a The difference in CV death and in non-CV death rates between 
genders is statistically significant (p = .0003)
b The difference in CV death and in non-CV death rates between 
Comorbidity index groups is statistically significant (p < 0.0001)
c The difference in CV death and in non-CV death rates according to 
presence/absence of revascularization is statistically significant (p < 
0.0001)
d The difference in CV death and in non-CV death rates according to 
PTCA or CABG is not statistically significant (p > 0.05)
e The difference in CV death and in non-CV death rates according to 
number of drugs classes claimed is statistically significant (p < 0.0001)BMC Cardiovascular Disorders 2006, 6:21 http://www.biomedcentral.com/1471-2261/6/21
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medication classes taken among those indicated for the
patient. They showed a clear association between an
increased score, corresponding to more treatment, and
decreased death rates after 6 months.
One can also observe that non cardiovascular survival is
increased with revascularization and cardioprotective
drugs. However, the extent of this increase is less impor-
tant than the one observed in cardiovascular survival. We
can put forward the hypothesis that the use of revascular-
ization and cardioprotective drugs can reflect a better
health care management in general, leading to an increase
in non cardiovascular survival as well as in cardiovascular
survival.
The major strength of this study is its "naturalistic" popu-
lation-based cohort. The use of these cohorts can produce
results reflecting more closely the real impact of treatment
in usual care. Although we acknowledge that validity may
possibly be threatened by multiple unrecognized biases,
the adjustment for age, sex and comorbidity index, as well
as the use of regression tree analysis provide us with more
comprehensive knowledge of the relationship between
usual care management and survival after a MI.
One of the logistic regression approach disadvantages is
that some variables may exert their effect on the whole
population while others may be relevant only in specific
subgroups (global and local effects). Indeed, for the logis-
tic regression approach, variables enter the equation as
main effects. Interactions can be added if they make sense
or if based on a priori specified hypothesis. This drawback
was overcome by using the regression tree approach [47-
49] which creates specific subpopulations according to
death rates. These regression tree analyses bring forward
some considerations on good care management in respect
to subpopulations. It also shows that there is not one bet-
ter treatment for all and that both revascularization and
cardioprotective drugs bring significant benefit alone or in
combination.
The major limitation of this study is inherent to the use of
administrative databases, for example, it was not possible
to take in consideration indication and contraindication
of revascularization procedures and cardioprotective
drugs according to specific clinical condition (STEMI/
NSTEMI).
Conclusion
This study reveals that, when considering usual care for
MI, survival is positively correlated with revascularization
and the number of cardioprotective drug classes claimed.
In this study, important predictors of cardiovascular death
after 2 years were the absence of revascularization, older
age and higher comorbidity index.
Competing interests
This project has benefited from an unrestricted grant by
Merck Frosst Canada Ltd. This grant was part of a peer
reviewed grant obtained from GEOIDE Networks of Cent-
ers of Excellence of Canada. None of the authors received
salaries, consultation fees or any reimbursement from this
company, nor held any shares in this organization.
Authors' contributions
AV, TN, and JC conceived the study, JC performed the
analyses. All authors participated to the writing of the
manuscript. All authors read and approved the final ver-
sion of the manuscript.
Acknowledgements
This project was subsidized by the GEOIDE Network of Centers of Excel-
lence and Merck Frosst Canada Ltd. The principal investigator was sup-
ported by the Department of Family Medicine, Université de Sherbrooke; the 
Clinical Research Center, Sherbrooke University Hospital; and the Fonds de 
Recherche en Santé du Québec.
References
1. Fondation des maladies du Coeur: Le Fardeau croissant des maladies
cardiovasculaires et des accidents vasculaires cérébraux au Canada
Ottawa, Canada; 2003. 
2. Cannon CP, Gibson CM, Lambrew CT, Shoultz DA, Levy D, French
WJ, Gore JM, Weaver WD, Rogers WJ, Tiefenbrunn AJ: Relation-
ship of symptom-onset-to-balloon time and door-to-balloon
Table 4: Time to death from all cause and time to cardiovascular (CV) death: Cox proportional hazard models (n = 5596)
Time to CV death
Crude HR (95% CI) Adjusted HR* (95% CI)
Age 1.087 (1.076;1.099) 1.069 (1.057;1.082)
Male gender 0.785 (0.669;0.921) 1.010 (0.857;1.190)
Comorbidity index 1.315 (1.271;1.362) 1.266 (1.222;1.312)
Revascularization (PTCA or CABG) 0.232 (0.165;0.324) 0.368 (0.261;0.518)
Number of classes of medication 0.749 (0.696;0.806) 0.853 (0.790;0.920)
* Adjusted for all covariablesBMC Cardiovascular Disorders 2006, 6:21 http://www.biomedcentral.com/1471-2261/6/21
Page 7 of 9
(page number not for citation purposes)
time with mortality in patients undergoing angioplasty for
acute myocardial infarction.  JAMA 2000, 283(22):2941-7.
3. Goldberg RJ, Mooradd M, Gurwitz JH, Rogers WJ, French WJ, Barron
HV, Gore JM: Impact of time to treatment with tissue plas-
minogen activator on morbidity and mortality following
acute myocardial infarction (The second National Registry
of Myocardial Infarction).  Am J Cardiol 1998, 82(3):259-64.
4. Gunnar RM, Passamani ER, Bourdillon PD, Pitt B, Dixon DW, Rapa-
port E, Fuster V, Reeves TJ, Karp RB, Russell RO Jr, Guidelines for the
early management of patients with acute myocardial infarction, et al.:
A report of the American College of Cardiology/American
Heart Association Task Force on Assessment of Diagnostic
and Therapeutic Cardiovascular Procedures.  J Am Coll Cardiol
1990, 16:249-292.
Predictors of 2-year cardiovascular (CV) death: Regression tree* and logistic regression approaches (n = 5596) Figure 4
Predictors of 2-year cardiovascular (CV) death: Regression tree* and logistic regression approaches (n = 5596). 
* The top number in the nodes represents the number of CV deaths and the number below is the total number of individuals 
in the specific class. CVDR: Cardiovascular death rate.BMC Cardiovascular Disorders 2006, 6:21 http://www.biomedcentral.com/1471-2261/6/21
Page 8 of 9
(page number not for citation purposes)
5. Mehta RH, Montoye CK, Gallogly M, Baker P, Blount A, Faul J, Roy-
choudhury C, Borzak S, Fox S, Franklin M, Freundl M, Kline-Rogers E,
LaLonde T, Orza M, Parrish R, Satwicz M, Smith MJ, Sobotka P, Win-
ston S, Riba AA, Eagle KA, for the GAP Steering Committee of the
American College of Cardiology: Improving quality of care for
acute myocardial infarction: the guidelines applied in prac-
tice (GAP) initiative.  JAMA 2002, 287(10):1269-76.
6. Ryan TJ, Antman EM, Brooks NH, Califf RM, Hillis LD, Hiratzka LF,
Rapaport E, Riegel B, Russell RO, Smith EE 3rd, Weaver WD, Gib-
bons RJ, Alpert JS, Eagle KA, Gardner TJ, Garson A Jr, Gregoratos G,
Ryan TJ, Smith SC Jr: 1999 update: ACC/AHA guidelines for the
management of patients with acute myocardial infarction. A
report of the ACC/AHA Task Force on practice guidelines.
J Am Coll Cardiol 1999, 34(3):890-911.
7. Whisenant BK, Wolfe CL: Acute myocardial infarction. Recom-
mendations for medical management and primary angi-
oplasty.  Postgrad Med 1997, 102(3):159-72.
8. Antoniucci D, Valenti R, Migliorini A, Moschi G, Trapani M, Buonamici
P, Cerisano G, Bolognese L, Santoro GM: Relation of time to
treatment and mortality in patients with acute myocardial
infarction undergoing primary coronary angioplasty.  Ameri-
can Journal of Cardiology 2002, 89(11):1248-1252.
9. Chodek A, Angioi M, Fajraoui M, Moulin F, Chouihed T, Maurer P,
Mejean C, Carteaux JP, Popovic B, Piquemal R, Ethevenot G, Aliot E:
Facteurs pronostiques de mortalite chez les patients en état
de choc cardiogenique primaire traites par angioplastie en
phase aigue d'infarctus.  Annales de Cardiologie et d Angeiologie
2005, 54(2):74-79.
10. De Luca G, Suryapranata H, Ottervanger JP, Antman EM: Time
delay to treatment and mortality in primary angioplasty for
acute myocardial infarction: every minute of delay counts.
[see comment].  Circulation 2004, 109(10):1223-1225.
11. Velianou JL, Wilson SH, Reeder GS, Caplice NM, Grill DE, Holmes
DR Jr, Bell MR: Decreasing mortality with primary percutane-
ous coronary intervention in patients with acute myocardial
infarction: the Mayo Clinic experience from 1991 through
1997. [see comment].  Mayo Clinic Proceedings 2000,
75(10):994-1001.
12. Steffenino G, Santoro GM, Maras P, Mauri F, Ardissino D, Violini R,
Chiarella F, Lucci D, Marini M, Baldasseroni S, Maggioni AP: In-hos-
pital and one-year outcomes of patients with high-risk acute
myocardial infarction treated with thrombolysis or primary
coronary angioplasty.  Ital Heart J 2004, 5(2):136-45.
13. Arós F, Marrugat J, López-Bescos L, Cabadés A, Loma-Osorio A,
Bosch X, the PRIAMHO Investigators: Accessibility to coronary
angiography and one-year survival after myocardial infarc-
tion.  Am J Cardiol 2002, 90(4):409-12.
14. Alter DA, Naylor CD, Austin PC, Tu JV: Long-term MI outcomes
at hospitals with or without on-site revascularization.  JAMA
2001, 285(16):2101-2108.
15. Yusuf S, Wittes J, Friedman L: Overview of results of randomised
clinical trials in heart disease. I. Treaments following myo-
cardial infarction.  JAMA 1988, 260(14):2088-2093.
16. Garg R, Yusuf S: Overwiew of randomised trials of angiotensin-
converting enzyme inhibitors on mortality and morbidity in
patients with heart failure. Collaborative Group on ACE
inhibitors trials.  JAMA 1995, 273:1450-1456.
17. Scandinavian Simvastatin Survival Study Group: Randomised trial of
cholesterol lowering in 4,444 patients with coronary heart
disease: The Scandinavian Simvastatin Survival Study (4S).
Lancet 1994, 344:1383-1389.
18. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford J, Cole TG,
Brown L, Warnica JW, Arnold JM, Wun CC, Davis BR, Braunwald E:
The effect of pravastatin on coronary events after myocar-
dial infarction in patients with average cholesterol levels.  N
Engl J Med 1996, 335:1001-1009.
19. Allen Maycock CA, Muhlestein JB, Horne BD, Carlquist JF, Bair TL,
Pearson RR, Li Q, Anderson JL, Intermountain Heart Collaborative S:
Statin therapy is associated with reduced mortality across all
age groups of individuals with significant coronary disease,
including very elderly patients.  Journal of the American College of
Cardiology 2002, 40(10):1777-1785.
20. Aronow HD, Topol EJ, Roe MT, Houghtaling PL, Wolski KE, Lincoff
AM, Harrington RA, Califf RM, Ohman EM, Kleiman N, Keltai M, Wil-
cox RG, Vahanian A, Armstrong PW, Lauer MS: Effect of lipid-low-
ering therapy on early mortality after acute coronary
syndromes: an observational study. [see comment].  Lancet
2001, 357(9262):1063-1068.
21. Bickel C, Rupprecht HJ, Blankenberg S, Espiniola-Klein C, Schlitt A,
Rippin G, Hafner G, Treude R, Othman H, Hofmann KP, Meyer J,
AtheroGene Investigators: Relation of markers of inflammation
(C-reactive protein, fibrinogen, von Willebrand factor, and
leukocyte count) and statin therapy to long-term mortality
in patients with angiographically proven coronary artery dis-
ease.  American Journal of Cardiology 2002, 89(8):901-908.
22. Bunch TJ, Muhlestein JB, Bair TL, Renlund DG, Lappe DL, Jensen KR,
Horne BD, Carter MA, Anderson JL, Intermountain Heart Collabora-
tive Study G: Effect of beta-blocker therapy on mortality rates
and future myocardial infarction rates in patients with coro-
nary artery disease but no history of myocardial infarction or
congestive heart failure.  American Journal of Cardiology 2005,
95(7):827-831.
23. Chan AW, Quinn MJ, Bhatt DL, Chew DP, Moliterno DJ, Topol EJ,
Ellis SG: Mortality benefit of beta-blockade after successful
elective percutaneous coronary intervention.  Journal of the
American College of Cardiology 2002, 40(4):669-675.
24. Coletta C, Ricci R, Ceci V, Seccareccia F, Rulli F, Mazzuca V, Putini RL,
Salustri A, Bottero G, Pasquale M: Effects of early treatment with
captopril and metoprolol singly or together on six-month
mortality and morbidity after acute myocardial infarction.
Results of the RIMA (Rimodellamento Infarto Miocardico
Acuto) study. The RIMA researchers. [see comment].  Gior-
nale Italiano di Cardiologia 1999, 29(2):115-124. discussion 125–119
25. Ellis K, Tcheng JE, Sapp S, Topol EJ, Lincoff AM: Mortality benefit of
beta blockade in patients with acute coronary syndromes
undergoing coronary intervention: pooled results from the
Epic, Epilog, Epistent, Capture and Rapport Trials.  Journal of
Interventional Cardiology 2003, 16(4):299-305.
26. Hague W, Forder P, Simes J, Hunt D, Tonkin A, LIPID Investigators:
Effect of pravastatin on cardiovascular events and mortality
in 1516 women with coronary heart disease: results from the
Long-Term Intervention with Pravastatin in Ischemic Dis-
ease (LIPID) study.  American Heart Journal 2003, 145(4):643-651.
27. Horne BD, Muhlestein JB, Carlquist JF, Bair TL, Madsen TE, Hart NI,
Anderson JL: Statin therapy, lipid levels, C-reactive protein
and the survival of patients with angiographically severe cor-
onary artery disease. [see comment].  Journal of the American
College of Cardiology 2000, 36(6):1774-1780.
28. Liu L, Chinese Cardiac Study Collaborative G: Long-term mortal-
ity in patients with myocardial infarction: impact of early
treatment with captopril for 4 weeks.  Chinese Medical Journal
2001, 114(2):115-118.
29. Otterstad JE, Ford I: The effect of carvedilol in patients with
impaired left ventricular systolic function following an acute
myocardial infarction. How do the treatment effects on total
mortality and recurrent myocardial infarction in CAPRI-
CORN compare with previous beta-blocker trials?  European
Journal of Heart Failure 2002, 4(4):501-506.
30. Stenestrand U, Wallentin L, Swedish Register of Cardiac Intensive C:
Early statin treatment following acute myocardial infarction
and 1-year survival.  JAMA 2001, 285(4):430-436.
31. Fonarow GC, Wright RS, Spencer FA, Fredrick PD, Dong W, Every
N, French WJ, National Registry of Myocardial Infarction 4 Investiga-
tors: Effect of statin use within the first 24 hours of admission
for acute myocardial infarction on early morbidity and mor-
tality.  Am J Cardiol 2005, 96(5):611-6.
32. Psaty BM, Anderson M, Kronmal RA, Tracy RP, Orchard T, Fried LP,
Lumley T, Robbins J, Burke G, Newman AB, Furberg CD: The asso-
ciation between lipid levels and the risks of incident myocar-
dial infarction, stroke, and total mortality: The
Cardiovascular Health Study.  J Am Geriatr Soc 2004,
52(10):1639-47.
33. Aronow WS, Ahn C, Kronzon I: Effect of propranolol versus no
propranolol on total mortality plus nonfatal myocardial inf-
arction in older patients with prior myocardial infarction,
congestive heart failure, and left ventricular ejection fraction
> or = 40% treated with diuretics plus angiotensin-converting
enzyme inhibitors.  Am J Cardiol 1997, 80(2):207-9.
34. Cleland JG, Erhardt L, Murray G, Hall AS, Ball SG: Effect of ramipril
on morbidity and mode of death among survivors of acute
myocardial infarction with clinical evidence of heart failure.Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
BMC Cardiovascular Disorders 2006, 6:21 http://www.biomedcentral.com/1471-2261/6/21
Page 9 of 9
(page number not for citation purposes)
A report from the AIRE Study Investigators.  Eur Heart J 1997,
18(1):41-51.
35. Matts JP, Buchwald H, Fitch LL, Campos CT, Varco RL, Campbell GS,
Pearce MB, Yellin AE, Smink RD Jr, Sawin HS Jr, Long JM, for The
Posch Group: Subgroup analyses of the major clinical end-
points in the Program on the Surgical Control of the Hyper-
lipidemias (POSCH): overall mortality, atherosclerotic
coronary heart disease (ACHD) mortality, and ACHD mor-
tality or myocardial infarction.  J Clin Epidemiol 1995,
48(3):389-405.
36. Heart Protection Study Collaborative Group: MRC/BHF Heart
Protection Study of cholesterol lowering with simvastatin in
20,536 high-risk individuals: a randomised placebo-control-
led trial.  Lancet 2002, 360(9326):7-22.
37. Herlitz J, Dellborg M, Karlson BW, Lindqvist J, Karlsson T, Sanden W,
Sjolin M, Wedel H: Changes in the use of medications after
acute myocardial infarction: possible impact on mortality
after myocardial infarction and long-term outcome.  Coronary
Artery Disease 2001, 12(1):61-67.
38. Hognestad A, Dickstein K, Myhre E, Snapinn S, Kjekshus J, OPTI-
MAAL Investigators: Effect of combined statin and beta-blocker
treatment on one-year morbidity and mortality after acute
myocardial infarction associated with heart failure.  American
Journal of Cardiology 2004, 93(5):603-606.
39. Krause MW, Massing M, Kshirsagar A, Rosamond W, Simpson RJ Jr:
Combination therapy improves survival after acute myocar-
dial infarction in the elderly with chronic kidney disease.
Renal Failure 2004, 26(6):715-725.
40. Mukherjee D, Fang J, Chetcuti S, Moscucci M, Kline-Rogers E, Eagle
KA: Impact of combination evidence-based medical therapy
on mortality in patients with acute coronary syndromes.  Cir-
culation 2004, 109:745-9.
41. Levy AR, Tamblyn RM, Fitchett D, McLeod PJ, Hanley JA: Coding
accuracy of hospital discharge data for elderly survivors of
myocardial infarction.  Can J Cardiol 1999, 15(11):1277-82.
42. Petersen LA, Wright S, Normand SL, Daley J: Positive predictive
value of the diagnosis of acute myocardial infarction in an
administrative database.  J Gen Intern Med 1999, 14:555-8.
43. D'Hoore W, Bouckaert A, Tilquin C: Practical considerations on
the use of the Charlson Comorbidity index with administra-
tive data bases.  J Clin Epidemiology 1996, 49(12):1429-33.
44. Hosmer DW, Lemeshow S: Applied Logistic Regression New York:
Wiley & Sons; 1989. 
45. Zhang HP, Bracken M: Tree-based risk factor analysis of pre-
term delivery and small-for-gestational-age birth.  Am J Epide-
miol 1995, 141:70-8.
46. Zhang HP, Holford T, Bracken M: A tree-based method in pro-
spective studies.  Stat Med 1996, 15:37-50.
47. Nicolucci A, Carinci F, Ciampi A: Stratifying patients at risk of
diabetic complications: An integrated look at clinical, socio-
economic and care-related factors.  Diabetes Care 1998,
21(9):1439-44.
48. Breiman L, Friedman JH, Olshen RA, Stone C: Classification and Regres-
sion Trees Belmont, CA: Wadsworth International Group; 1984. 
49. Ciampi A, Hogg S, McKinney S, Thiffault J: RECPAM: a computer
program for recursive partition and amalgamation for cen-
sored survival data and other situations frequently occurring
in biostatistics. I. Methods and program features.  Comput
Methods Programs Biomed 1988, 26:239-56.
50. de Gevigney G, Ecochard R, Colin C, Rabilloud M, Excoffier S, Cao D,
Cheneau E, Milon H, Delahaye F, PRIMA group: Characteristics,
management, and inhospital mortality of acute myocardial
infarction in the "real world" in France – data from a large
unselected cohort of 2,519 consecutive patients in a French
region.  Acta Cardiol 2000, 55(6):357-66.
51. Dauerman HL, Yarzebski J, Gore JM, Lessard D, Goldberg RJ: Use of
the invasive management strategy for patients with non-Q-
wave myocardial infarction: an observational database
report from the Worcester Heart Attack Study.  Am Heart J
2002, 143(6):1033-9.
52. Amit G, Goldman S, Ore L, Low M, Kark JD: The association
between hospital department, medical treatment and out-
come in acute myocardial infarction.  Isr Med Assoc J 2003,
5(4):255-9.
53. Scott IA, Coory MD, Harper CM: The effects of quality improve-
ment interventions on inhospital mortality after acute myo-
cardial infarction.  Med J Aust 2001, 175(9):465-70.
54. Sheikh K, Bullock C: Urban-rural differences of care for medi-
care patients with acute myocardial infarction.  Arch Intern Med
2001, 161(5):737-53.
55. Vu HD, Heller RF, Lim LLY, D'este C, O'Connell RL: Mortality after
acute myocardial infarction is lower in metropolitan regions
than in non-metropolitan regions.  J Epidemiol Community Health
2000, 54:590-5.
56. Lim LLY, O'Connell RL, Heller RF: Differences in management of
heart attack patients between metropolitan and regional
hospitals in the Hunter Region of Australia.  Aust New Zeal J Pub
Health 1999, 23(1):61-6.
Pre-publication history
The pre-publication history for this paper can be accessed
here:
http://www.biomedcentral.com/1471-2261/6/21/prepub